In oral solid dosage operations, acetylisovaleryl tylosin tartrate is introduced as a spray-dried or air-milled powder with particle size controlled to D₉₀ ≤ 75 µm when direct compression is used, because larger crystals segregate in low-density filler matrices under forced-feeder agitation. Formulation trials frequently evaluate API fractions between 60 wt% and 80 wt%, with microcrystalline cellulose as filler-binder at 15–30 wt%, crospovidone disintegrant at 2–5 wt%, colloidal silicon dioxide at 0.5–1.0 wt%, and magnesium stearate at 0.5–1.0 wt%. On a 10-station rotary tablet press equipped with 9 mm concave tooling and a forced feeder, precompression force is set at 2.5–5.0 kN, main compression force at 8–18 kN, and turret speed at 25–45 rpm to achieve tablet hardness 8–12 kp; friability is maintained at ≤1.0% under USP <1216>. The tartrate salt can accelerate moisture uptake at relative humidity above 60%; direct compression suites are therefore maintained at 20–25°C and <40% RH to prevent punch filming and sticking. Dissolution testing is conducted with USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 1.2 simulated gastric fluid without pepsin, because lactone-ring hydrolysis in acid media is a critical quality risk that must be separated from formulation-driven release failure.

What Changes When the API Is Processed as a Wet Granulation Intermediate?

Wet granulation of a tartrate salt API shifts the primary processing risk from blend segregation to moisture-mediated degradation and binder migration. In a high-shear granulator with a 2 L bowl and bottom-driven impeller, impeller tip speed is held at 3–8 m/s, while a side chopper at 1500–3000 rpm limits lump formation. Binding fluid is added at 8–15 wt% of dry mass; if an aqueous binder is used, a 5–10 wt% solution of hypromellose 3 mPa·s or povidone K30 is sprayed at 10–20 g/min. Endpoint is determined by power consumption and impeller torque increase of 15–30% relative to dry-mixing baseline, not by fixed granulation time, because the tartrate salt can produce variable wet-mass viscosity. Granules are wet-milled through a 1.0–1.5 mm screen, transferred to a fluid-bed dryer with inlet air temperature 55–75°C, and dried to loss-on-drying 1.0–3.0% at product temperature 30–45°C. Hydroalcoholic binder systems, when required for low aqueous solubility, introduce residual ethanol and isopropanol; ICH Q3C Class 2 and Class 3 solvent limits are verified by gas chromatography after drying. The acid-sensitive lactone ring is protected during granulation by buffering the granulation fluid at pH 5.0–6.5 with citrate or phosphate buffer; no terminal wet-mass holding period exceeding 60 min before drying should be accepted unless forced-degradation data demonstrate otherwise.

Sterile Injectable Solution Design and Terminal Filtration Risk

The formulation path for a terminally injectable solution from a tartrate-salt macrolide is determined by vehicle pH, oxygen exclusion, and sterilization mode. The tartrate counterion can provide aqueous solubility above 100 mg/mL at 20°C when the vehicle pH is maintained between 4.5 and 6.5; published solubility data for this specific derivative are limited and should be confirmed by shake-flask equilibrium testing according to OECD 105. Vehicle tonicity is adjusted with sodium chloride or dextrose to target osmolality 280–320 mOsm/kg; if dextrose is used, fill volume and headspace oxygen level are controlled because macrolide lactone rings are susceptible to oxidative degradation. Terminal moist-heat sterilization at 121°C for 15 min may exceed the thermal stability boundary of this acetylated derivative; forced-degradation studies under ICH Q1A and Q1B should compare pH-degradation kinetics at 60°C, 80°C, and 40°C/75% RH before the sterilization route is fixed. Where terminal sterilization is not justified, aseptic filtration through a 0.45 µm polyethersulfone prefilter and a 0.22 µm sterilizing-grade PVDF membrane is used. Filter compatibility testing per PDA Technical Report 26 includes extractables screening, bacterial retention validation with Brevundimonas diminuta, and maximum filtration pressure 2.0–3.0 bar. Filled vials are processed in an EU GMP Annex 1 Grade A environment with unidirectional airflow 0.36–0.54 m/s and glove-port interventions documented in the batch record. For a lyophilized injection, the solution is filled to partial volume, frozen at -45°C to -40°C with a shelf ramp of 0.5–1.0°C/min, annealed at -20°C to -10°C for 2–4 h, primary-dried at chamber pressure 80–120 mTorr with shelf temperature -30°C to -10°C, and secondary-dried at 25–35°C for 4–8 h. Cake collapse temperature determined by freeze-drying microscopy must guide chamber pressure, because the tartrate salt can depress the eutectic point in concentrated formulations.

Low Humidity Turns Capsule Powder Triboelectrics into a Weight Variability Fault

At relative humidity below 35% RH, capsule filling of a tartrate salt granulate induces triboelectric charge accumulation because the API and filler particles are insulators with high surface resistivity. On an intermittent-motion dosator capsule filling machine configured for size 0 or size 1 hard gelatin or HPMC capsules, fill weight targets between 250 mg and 500 mg require powder bed depth and dosator compression length to be locked after the first 200 cycles; weight variability above 3% RSD indicates electrostatic clumping rather than primary flow failure. Processing rooms are maintained at 20–25°C and 35–50% RH; below 30% RH, charge decay time can exceed 10 s, and powder may adhere to stainless steel dosator bores. Excipient selection uses pregelatinized starch 5–15 wt% as filler-binder, croscarmellose sodium 2–4 wt% as disintegrant, and magnesium stearate 0.5–1.0 wt% as lubricant; if the hydrophobic lubricant is overmixed above 5 min, capsule dissolution may slow because the API particles become coated. Blend flow is quantified by Hausner ratio <1.25 and Carr index <25, with shear cell flow function coefficient 4–10 measured per ASTM D6128-16. Capsules are checked for weight variation according to USP <905> and for dissolution with USP <711> Apparatus 2 at 50 rpm in 900 mL of pH 1.2 simulated gastric fluid without pepsin. The tartrate salt is hygroscopic; pre-drying at 40–50°C for 2–4 h and storage in sealed drums with desiccant before filling are used to maintain water content below 3.0% by Karl Fischer USP <921> Method 1a.

When Granule Dose Uniformity in Multi-Unit Sachets Becomes the Critical Release Attribute

Distribution of active granules across multi-unit sachets creates a risk of both inter-sachet segregation and intra-sachet moisture migration. Granule fractions for sachet filling are sized between 150 µm and 710 µm; the proportion outside this range is held below 15% because coarse granules bridge the filler and fine granules percolate to the bottom. A vertical form-fill-seal stick-pack line with a reciprocating auger or volumetric cup filler is set to a fill weight of 1.0–5.0 g with an in-process checkweigher rejection limit of ±3% relative to target. The API content in each sachet must meet USP <905> acceptance value ≤15; this is achieved by maintaining granule bulk density between 0.45 g/cm³ and 0.65 g/cm³ and by adding 0.5–1.0 wt% hydrophobic fumed silica as flow and anti-caking agent. If the granule is filled into laminated aluminum stick packs, oxygen transmission rate below 0.5 cm³/m²/day and moisture vapor transmission rate below 0.5 g/m²/day are specified to limit oxidation and hydrolysis of the macrolide lactone ring. Each pallet is sampled for moisture by Karl Fischer USP <921> Method 1a; granular water content above 3.0% triggers a reprocessing decision because stick-pack headspace is small and water migration from the granule surface accelerates degradation. Dissolution testing of the sachet content is conducted with USP <711> Apparatus 2 at 50 rpm; if the granule formulation contains a pH-dependent coating, dissolution is run in 900 mL of 0.1 N HCl for 30 min followed by pH 6.8 phosphate buffer.

Does Dry Syrup Reconstitution Create a Zeta Potential Collapse in Sorbitol Vehicles?

After reconstitution with potable water to the mark, the dry syrup intermediate containing the tartrate salt is evaluated for zeta potential, apparent viscosity, and pH. Dry syrup powder is milled through a 180 µm screen before dry blending with sorbitol or sucrose, a suspending agent, and buffering species. Zeta potential measured with a Malvern Zetasizer or equivalent should show absolute values between 20 mV and 40 mV to prevent irreversible caking at the bottle base. Apparent viscosity measured with a Brookfield LV viscometer, spindle 2 at 30 rpm, is adjusted with xanthan gum or microcrystalline cellulose/carboxymethylcellulose sodium to 300–800 mPa·s at 25°C; values above 1000 mPa·s make pourability difficult for oral dosing, while values below 200 mPa·s permit rapid sedimentation. pH is buffered to 4.5–6.0 with citric acid/sodium citrate, because acid conditions below 4.0 accelerate lactone ring hydrolysis. In-use stability after reconstitution is established by exposing the suspension to 2–8°C and 25°C/60% RH for 7–14 days; if microbial quality is at risk, potassium sorbate or sodium benzoate is included at 0.1–0.2% per preservative efficacy testing under USP <51>. The dry powder is tested for microbial limits under USP <61> and USP <62> before release, and sedimentation volume ratio is required to remain above 0.9 after 24 h at 25°C.